Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson’s disease: a meta-analysis
Autor: | Ming-Xing Li, De-Qi Jiang, Xiao-Bai Chen, Li-Lin Jiang, Xing-Wen Zhou |
---|---|
Rok vydání: | 2019 |
Předmět: |
Aging
Levodopa medicine.medical_specialty Combination therapy law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Activities of Daily Living Selegiline medicine Humans 030212 general & internal medicine Adverse effect business.industry Parkinson Disease Odds ratio Mental Status and Dementia Tests Combined Modality Therapy Confidence interval Clinical trial Treatment Outcome Drug Therapy Combination Geriatrics and Gerontology business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Aging Clinical and Experimental Research. 32:769-779 |
ISSN: | 1720-8319 |
DOI: | 10.1007/s40520-019-01232-4 |
Popis: | Selegiline or levodopa treatment has been suggested as a therapeutic method for Parkinson’s disease (PD) in many clinical trial reports. However, the combined effects of two drugs still remain controversial. The aim of this report was to evaluate the clinical efficacy and safety of selegiline plus levodopa (S + L) combination therapy in the treatment of PD compared to that of L monotherapy, to provide a reference resource for rational drug use. Randomized controlled trials (RCTs) of S + L for PD published up to September, 2018 were searched. Mean difference (MD), odds ratio (OR), and 95% confidence interval (CI) were calculated and heterogeneity was assessed with the I2 test. Sensitivity analysis was also performed. The outcomes measured were as follows: the unified Parkinson’s disease rating scale (UPDRS) scores, modified Webster score, adverse events and mortality. Fourteen RCTs with 2008 participants were included. Compared with L monotherapy, the pooled effects of S + L combination therapy on UPDRS score were (eleven trials; MD − 7.00, 95% CI − 8.35 to − 5.65, P |
Databáze: | OpenAIRE |
Externí odkaz: |